IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A method of detecting an anti-mycobacterial CD8 T cell response comprising contacting a population of CD8 T cells of a human individual with one or more peptides selected from the group consisting of ~~peptides of~~ SEQ ID NOS:3, 4, 7, 8, 9, 10, 11 and 12, and, optionally, one or two further peptides selected from the group consisting of SEQ ID NOS:1 and [[/or]] 2, wherein one or more ~~of said~~ peptides may be substituted by an analogue which binds a T cell receptor that recognizes the peptide, and determining whether CD8 T cells of the CD8 T cell population recognize the peptide(s).

Claim 2 (canceled)

3. (currently amended) A method according to claim 1 wherein a peptide panel is employed comprising [[the]] peptides of the sequences SEQ ID NOS:1, 2, 3, 4, 8, 9 and 10, wherein one or more ~~of these~~ peptides may be substituted by said analogue.

4. (previously presented) A method according to claim 1 wherein any analogue which is used is (i) at least 70% homologous, preferably at least 80% homologous, more preferably at least 90% homologous, to the entire peptide, and/or (ii) has one or more deletions at the N-terminus and/or C-terminus in comparison to the peptide, and/or (iii) has one or more conservative substitutions compared to the peptide.

5. (previously presented) A method according to claim 1 in which the recognition of the peptide(s) by the CD8 T cells is determined by measuring secretion of a cytokine from the CD8 T cells.

6. (previously presented) A method according to claim 5 in which IFN-γ secretion from the T cells is measured.

7. (previously presented) A method according to claim 6 in which IFN-γ secretion from the CD8 T cells is determined by allowing secreted IFN-γ to bind an immobilized antibody specific to the cytokine and then determining the presence of antibody/cytokine complex.

8. (original) A method according to claim 1 in which the CD8 T cells are freshly isolated *ex vivo* cells from peripheral blood.

9. (original) A method according to claim 1 in which CD8 T cells are pre-cultured *in vitro* with the peptide(s).

10. (original) A method according to claim 1 in which the mycobacterium is *M. tuberculosis*.

11. (original) A method according to claim 1 wherein the population of CD8 T cells is from an individual to whom an anti-mycobacterial vaccine has been administered.

12. (original) A method according to claim 1 which is carried out *in vitro*.

Claim 13 (canceled)

14. (currently amended) A kit ~~for carrying out a method according to claim 1~~ comprising one or more peptides selected from the group consisting of ~~peptides of~~ SEQ ID NOS:3, [[4,]] [[7,]] 8, 9, 10, 11 and 12, and, optionally, one or two further peptides selected from the group consisting of SEQ ID NOS:1 and [[/or]] 2, wherein one or more ~~of said~~ peptides may be substituted by an analogue which binds a T cell receptor which recognizes the peptide, and optionally a means to detect recognition of the peptide(s) by CD8 T cells.

Claim 15 (canceled)

16. (currently amended) A kit ~~according to claim 14~~ comprising a peptide panel comprising [[the]] peptides of the sequences SEQ ID NOS:1, 2, 3, 4, 8, 9 and 10, wherein one or more ~~of these~~ peptides may be substituted by said analogue.

17. (original) A kit according to claim 14 which includes an antibody to IFN-γ.

18. (previously presented) A kit according to claim 17 wherein said antibody is immobilized on a solid support and which optionally also includes a means to detect any antibody/IFN-γ complex.

Claims 19-27 (canceled)

28. (previously presented) A kit according to claim 14 which includes the means to detect recognition of the peptide(s) by CD8 T cells.

29. (previously presented) A kit according to claim 17 which includes the means to detect recognition of the peptide(s) by CD8 T cells.

30. (previously presented) A kit according to claim 18 which includes the means to detect any antibody/IFN-γ complex.

31. (new) A method according to claim 1 wherein the one or more peptides are comprised of one or more sequences selected from the group consisting of SEQ ID NOS:3, 4, 7, 8, 9, 10, 11 and 12.

32. (new) A method according to claim 1 wherein the one or more peptides are comprised of one or more sequences selected from the group consisting of SEQ ID NOS:3, 4, 8, 9 and 10.

33. (new) A kit according to claim 14 wherein the one or more peptides are comprised of one or more sequences selected from the group consisting of SEQ ID NOS:3, 8, 9, 10, 11 and 12.

34. (new) A kit according to claim 14 wherein the one or more peptides are comprised of one or more sequences selected from the group consisting of SEQ ID NOS:3, 8, 9 and 10.